GeneDx Shares Slide After Tempering of FY Outlook

Dow Jones11-11
 

Shares of GeneDx Holdings fell after the rare-disease-diagnosis company tempered its full-year outlook and widened its third-quarter loss.

The stock fell 16%, to $55.26, in midday trading Tuesday. Shares are down 58% year to date.

GeneDx late Monday said it widened its quarterly loss to $12.3 million, or 41 cents a share, from a loss of $7.64 million, or 27 cents a share, a year earlier.

Stripping out one-time items, the company reported quarterly earnings of 28 cents a share. Analysts polled by FactSet expected adjusted earnings of 7 cents a share.

Total revenue climbed 5.5% to $123.1 million, ahead of Wall Street models for $122.9 million.

Exome and genome test revenue increased 12% from last year, to $110.4 million, while test-result volume increased 25%, to 32,134.

Looking ahead, GeneDx maintained its outlook for full-year revenue of $475 million to $490 million, compared with analyst views for $477.7 million. However, its fourth-quarter revenue expectation of $135 million missed Wall Street estimates for $142.6 million.

The company also tempered its 2026 guidance for its exome and genome test business. It now expects full-year revenue growth in the segment of at least 17%, down from a prior outlook for at least 20% growth, as well as test-result volume growth of at least 28%, down from a previous forecast for at least 30% growth.

 
 

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment